CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Dynogen Pharmaceuticals
Dynogen developed a portfolio of therapies for gastrointestinal and genitourinary disorders. It went out of business in 2009.
Dynogen Pharmaceuticals
Waltham, MA
